Clinical Trial Update: ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating ER Niacin/Laropiprant impact on cardiovascular markers and atheroprogression in HIV-infected individuals on cART; study termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• HIV Infection

Drugs mentioned

• ER Niacin (extended-release niacin)
• Laropiprant (laropiprant)

Snippet

Sponsor: Calmy Alexandra | Conditions: HIV, Atherosclerosis | Phase 4 | Status: TERMINATED